Adherence in SPAF: Measures to Improve Care

Slides:

Advertisements

Similar presentations

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.

Advertisements

Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.

AF and NOACs An UPDATE JULY 2014

Improving Stroke Prevention in Patients With Atrial Fibrillation.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Gli anticoagulanti diretti nel mondo reale

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

How Do We Incorporate Patient Perspectives Into Clinical Trial Design?

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Addressing the Challenges in Primary and Secondary Stroke Prevention

American Heart Journal

Covering the Bases in Cardioversion

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Silent No More:.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

NOACs for Cancer-Associated Thrombosis:

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

How to Adjust Anticoagulant Dosing

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

VTE Treatment Conventional Approach

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Access to NOAC Therapy:

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

What Anticoagulant Registries Are Revealing

Watching for the Patient With AF: Latest Advances and Technologies

Learning Objectives Classification of VTE Goals of VTE Treatment.

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Taking the "Cryptogenic" Out of Cryptogenic Stroke

NOACs in AF: Consequences of Underdosing and NonAdherence

Anticoagulation and Thrombosis Management

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOACs in AF: Consequences of Underdosing and NonAdherence

Improving Adherence to Antiplatelet Therapy After an ACS Event

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

How to Adjust Anticoagulant Dosing

Real-World Data in Cardiology: Focus on Atrial Fibrillation

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Presentation transcript:

Adherence in SPAF: Measures to Improve Care

Most Ischemic Strokes Occur in Patients Who Are Suboptimally Anticoagulated

Initiation and Persistence of Warfarin or Aspirin in Patients With Chronic AF

Patient's Values and Preferences in SPAF

Attitudes Toward Stroke Prevention and Bleeding Risk in Patients With AF

TREAT: Patients' Knowledge of AF Treatment and Control

TREAT: Educational Intervention Improves Anticoagulation Control

Approved NOACs for SPAF in Patients With Nonvalvular AF

Veterans Health Administration: Adherence To Dabigatran Therapy

Danish Nationwide Cohort Study: Dabigatran Adherence in AF

AEGEAN: Effect of Education on Apixaban Adherence in NVAF

AEGEAN: Persistence Rates in Patients Given Additional Education

Working With Your Patients on Adherence in SPAF

Abbreviations

Abbreviations (cont)